ARS Pharmaceuticals (SPRY) risk factors

71 risks, 6 new, 1 dropped, 17 reworded since the prior year. The company faces heightened commercialization risks as neffy is its only approved product, relying heavily on global supply chains and collaboration partners. Regulatory scrutiny has intensified, notably with FDA untitled letters regarding TV advertisements and potential pricing pressures. Financial exposure includes a $100.0 million credit agreement and macroeconomic uncertainties impacting debt or equity financing.

66 risks. ARS Pharmaceuticals relies heavily on the commercial success of its single approved product, neffy, an intranasal epinephrine spray. The company faces significant risks from third-party dependency for manufacturing and distribution, uncertain pricing and reimbursement, and intellectual property protection.